Infliximab in refractory spondyloarthropathies: A multicentre 38 week open study

Annals of the Rheumatic Diseases

Volumn 62, Issue 12, 2003, Pages 1239-1240

  Collantes Estevez E ^a   Munoz Villanueva M C ^a   Canete Crespillo J D ^b   Sanmarti Sala R ^b   Gratacos Masmitja J ^c   Zarco Montejo, P ^d   Torre Alonso, J C ^e   Gonzalez Fernandez C ^f  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Rheumatology Service   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e Rheumotology Service   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CHORIORETINITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HUMAN; LIVER TOXICITY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSTATITIS; SPONDYLOARTHROPATHY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; SPONDYLARTHROPATHIES; THORACIC VERTEBRAE;

EID: 17344394440     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2002.004879     Document Type: Article

References (8)

1. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database collaborative arthritis centres. J Rheumatol 2000;27:613-22.
2. Dougados M. Disease controlling antirheumatic therapy in spondyloarthropathy. J Rheumatol 2001;28(suppl 62):16-20.
3. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active onkylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
4. Van den Bosch F, Kruithof E, Baeten D, Herssens A, Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
5. Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, et al. Antitumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 2002;61(suppl III):iii51-60.
6. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995;1:117-28.
7. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF 36). Conceptual framework and item selection. Med Care 1992;30:473-83.
8. Anderson JJ, Baron G, Van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.